SCHEMBL6892407

SCHEMBL6892407

CCCOC(=O)Oc1ccc2c(c1)CCC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.49
POLB P06746 2/20 0.48
KDM4E B2RXH2 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MMP2 P08253 1/20 0.46
MMP9 P14780 1/20 0.46
MMP14 P50281 1/20 0.46
ALDH1A1 P00352 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
PPARG P37231 3/20 0.45
PPARD Q03181 3/20 0.45
PPARA Q07869 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
RXRA P19793 3/20 0.44
RXRB P28702 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6891449 0.88 POLB (0.50) MAPTPOLBKDM4ESMN1; SMN2ALOX15
SCHEMBL11653596 0.82 SMN1; SMN2 (0.58) MAPTPOLBKDM4ESMN1; SMN2ALOX15
SCHEMBL442937 0.82 SMN1; SMN2 (0.49) MAPTPOLBKDM4ESMN1; SMN2ALOX15
SCHEMBL6891790 0.82 SMN1; SMN2 (0.49) MAPTPOLBKDM4ESMN1; SMN2ALOX15
SCHEMBL6890994 0.80 POLB (0.54) MAPTPOLBKDM4ESMN1; SMN2ALOX15
SCHEMBL9719992 0.79 ALOX15 (0.59) MAPTPOLBKDM4ESMN1; SMN2ALOX15
SCHEMBL31306144 0.78 ALOX15 (0.51) MAPTPOLBKDM4ESMN1; SMN2ALOX15
SCHEMBL27559440 0.78 ALOX15 (0.51) MAPTPOLBKDM4ESMN1; SMN2ALOX15
SCHEMBL6892404 0.78 SMN1; SMN2 (0.46) MAPTPOLBKDM4ESMN1; SMN2ALOX15
SCHEMBL6890990 0.78 SMN1; SMN2 (0.54) MAPTPOLBKDM4ESMN1; SMN2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677331-B2 HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS MEIJI SEIKA KAISHA, LTD. (JP) 2004-01-13 US disclosed
US-20030149016-A1 Novel carbapenem derivatives KANO YUKO (JP) 2003-08-07 US disclosed
US-6458780-B1 IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND MEIJI SEIKA KAISHA, LTD. (JP) 2002-10-01 US disclosed
EP-1101766-A1 NOVEL CARBAPENEM DERIVATIVES MEIJI SEIKA KAISHA LTD. (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149016-A1 Novel carbapenem derivatives DPEP1, TMPRSS15, STK35 MAPT 4427/4885POLB 2952/4885KDM4E 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.